Showing results (111-120 of 151) with videos related to
Sort By:
Pageof 16
International Journal of Pharmaceutics|May 10, 2000
Formulation and process considerations for beads containing Carbopol 974P, NF resin made by extrusion-spheronizationS H Neau, M Y Chow, G A Hileman, et al.British Journal of Haematology|February 1, 1995
Erythropoietin gene expression in fetal and adult sheep kidneyI A Darby, B A Evans, P Fu, et al.Genomics|March 21, 1998
Mapping the gene for sex-linked anemia: an inherited defect of intestinal iron absorption in the mouseG J Anderson, T L Murphy, L Cowley, et al.Hormone Research|January 1, 1993
Deficiency of 17-ketoreductase presenting before pubertyJ W Gregory, A Aynsley-Green, B A Evans, et al.Journal of Clinical Pharmacology|April 1, 1987
Determination of the in vivo Km and Vmax of a drug with tracer studiesT R Browne, D Greenblatt, J E Evans, et al.Mayo Clinic Proceedings|November 1, 1994
Transient ischemic attack and minor ischemic stroke: an algorithm for evaluation and treatment. Mayo Clinic Division of Cerebrovascular DiseasesR D Brown, B A Evans, D O Wiebers, et al.Human Molecular Genetics|February 1, 1996
Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndromeC L Bevan, B B Brown, H R Davies, et al.The Prostate|March 1, 1996
Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysisB A Evans, M E Harper, C E Daniells, et al.Journal of Clinical Pharmacology|January 1, 1985
Studies with stable isotopes I: Changes in phenytoin pharmacokinetics and biotransformation during monotherapyT R Browne, J E Evans, G K Szabo, et al.Journal of Clinical Pharmacology|April 1, 1987
Estimation of the elimination half-life of a drug at any serum concentration when the Km and Vmax of the drug are known: calculations and validation with phenytoinT R Browne, D J Greenblatt, J E Evans, et al.Pageof 16